Volume 12, Number 10—October 2006
Research
Active Cytomegalovirus Infection in Patients with Septic Shock
Table
Characteristics and clinical course of patients with septic shock, with and without active CMV infection*
| Active CMV infection | No active CMV infection | Significance | ||
|---|---|---|---|---|
| No. patients | 8 | 17 | ||
| CMV IgG, index | 12.4 (5.4–14.7) | 11.7 (1.5–18.3) | NS† | |
| CMV IgM, index | 0.4 (0.28–3.94) | 0.28 (0.2–1.8) | NS† | |
| Sex, n | ||||
| Male | 5 | 10 | NS‡ | |
| Female | 3 | 7 | NS‡ | |
| Age, y | 66 (40–78) | 60 (44–78) | NS† | |
| Primary condition, n | ||||
| Abdominal surgery | 1 | 7 | NS‡ | |
| Abdominal tumor | 1 | 4 | NS‡ | |
| Pancreatitis | 3 | 1 | NS‡ | |
| Trauma | 2 | 5 | NS‡ | |
| Vascular surgery | 1 | 0 | NS‡ | |
| Bacteremia, n (%) | 4 (50) | 10 (59) | NS‡ | |
| Candidemia, n (%) | 2 (25) | 1 (6) | NS‡ | |
| SOFA score§ | 10 (7–13) | 10 (7–16) | NS‡ | |
| Leukocyte count, g/L§ | 27 (10.4–53.3) | 22.4 (7.2–74.3) | NS† | |
| Platelet count, g/L¶ | 106 (37–151) | 112 (37–385) | NS† | |
| Serum creatinine, μmol/L§ | 183 (73–345) | 160 (72–347) | NS† | |
| Serum bilirubin, μmol/L§ | 27 (6–279) | 54 (4–336) | NS† | |
| Aspartate aminotransferase, U/L§ | 55 (7–267) | 45 (9–229) | NS† | |
| C-reactive protein, mg/L§ | 258 (16–456) | 220 (115–437) | NS† | |
| ICU stay after onset of septic shock, d | 42 (16–87) | 18 (10–42) | p = 0.0025† | |
| Mechanical ventilation, d | 39 (15–80) | 16 (5–38) | p = 0.0025† | |
| Receipt of catecholamines, d | 7 (4–41) | 7 (1–35) | NS† | |
| Mortality rate, n (%) | 5 (63) | 6 (35) | NS‡ | |
| HSV reactivation, n (%) | 6 (75) | 2 (12) | p = 0.0036‡ | |
*Median (range), unless otherwise indicated; CMV, cytomegalovirus; Ig, immunoglobulin; NS, not significant (p>0.05); SOFA, sepsis-related organ failure assessment; ICU, intensive care unit; HSV, herpes simplex virus.
†According to Mann-Whitney U test.
‡According to Fisher exact test.
§Highest values.
¶Lowest values.


